scorecardresearch
Follow Us:
Friday, June 18, 2021

DRDO’s Covid treatment drug gets emergency use nod

DRDO, in a statement on Saturday, said the 2-deoxy-D-glucose (2-DG) drug can provide early relief from oxygen dependency among the patients, which can be helpful as the second Covid-19 wave rages on across the country, and more patients continue to need medical oxygen.

By: Express News Service | New Delhi |
May 9, 2021 12:59:30 am
The Drugs Controller General of India (DCGI) granted emergency use permission on May 1, “as adjunct therapy in moderate to severe” patients”.

The Country’s drug regulator has approved an oral drug developed by the Defence Research and Development Organisation (DRDO) for emergency use for adjunct treatment of moderate to severe Covid positive patients.

DRDO, in a statement on Saturday, said the 2-deoxy-D-glucose (2-DG) drug can provide early relief from oxygen dependency among the patients, which can be helpful as the second Covid-19 wave rages on across the country, and more patients continue to need medical oxygen.

The Drugs Controller General of India (DCGI) granted emergency use permission on May 1, “as adjunct therapy in moderate to severe” patients”. The drug has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories, Hyderabad.

The DRDO statement mentioned that “clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence” and a “higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients”.

Scientists of INMAS-DRDO conducted laboratory experiments in April 2020, the first wave of the pandemic, with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Phase 2 trials were conducted in May-October last and it was found that the drug was safe for Covid-19 patients, who showed significant improvement in recovery.

“In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC.” DRDO said.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement